CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA022212 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA022212.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: DIFLUPREDNATE OPHTHALMIC (DIFLUPREDNATE OPHTHALMIC) — Type 1 - New Molecular Entity

Policy FDA-NDA022212 · Ophthalmology

High

Difluprednate ophthalmic emulsion (Sandoz NDA022212) is administered via the ophthalmic route, which supports a Part D billing pathway as indicated. As an ophthalmic corticosteroid emulsion, it is typ

View alert

Audit documentation

Building an audit file that includes FDA-NDA022212?

The Tripwire Audit Pack exports 12 months of Ophthalmology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Ophthalmology audit pack — $349One-time purchase · not a subscription